keyword
MENU ▼
Read by QxMD icon Read
search

drug eluting stents

keyword
https://www.readbyqxmd.com/read/27933192/randomised-comparison-of-drug-eluting-versus-bare-metal-stenting-in-patients-with-non-st-elevation-myocardial-infarction
#1
Wouter S Remkes, Erik A Badings, Renicus S Hermanides, Saman Rasoul, Jan-Henk E Dambrink, Petra C Koopmans, Salem Hk The, Jan Paul Ottervanger, A T Marcel Gosselink, Jan Ca Hoorntje, Harry Suryapranata, Arnoud Wj van 't Hof
OBJECTIVE: The superiority of drug-eluting stents (DES) over bare-metal stents (BMS) in patients with ST elevation myocardial infarction (STEMI) is well studied; however, randomised data in patients with non-ST elevation myocardial infarction (NSTEMI) are lacking. The objective of this study was to investigate whether stenting with everolimus-eluting stents (EES) safely reduces restenosis in patients with NSTEMI as compared to BMS. METHODS: ELISA-3 patients were asked to participate in the angiographic substudy and were randomised to DE (Xience V) or BM (Vision) stenting (ELISA-3 group)...
2016: Open Heart
https://www.readbyqxmd.com/read/27932532/late-restenosis-after-both-first-generation-and-second-generation-drug-eluting-stent-implantations-occurs-in-patients-with-drug-eluting-stent-restenosis
#2
Seiji Habara, Kazushige Kadota, Akimune Kuwayama, Takenobu Shimada, Masanobu Ohya, Katsuya Miura, Hidewo Amano, Shunsuke Kubo, Yusuke Hyodo, Suguru Otsuru, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto
BACKGROUND: There are currently inadequate data about whether late restenosis occurs after drug-eluting stent (DES) implantation in patients with DES restenosis. METHODS AND RESULTS: We collected data for 608 patients who received revascularization for DES restenosis between 2004 and 2012 and analyzed 688 lesions: 359 lesions treated with a first-generation DES (first DES) and 329 lesions treated with a second-generation DES (second DES). Two serial angiographic follow-ups were routinely planned for the patients (at 8 and 20 months after the procedure)...
December 2016: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/27928256/one-year-outcome-of-everolimus-eluting-stents-versus-biolimus-eluting-stents-in-patients-undergoing-percutaneous-coronary-intervention
#3
Mohammad Alidoosti, Vahideh Sharifnia, Seyed Ebrahim Kassaian, Alimohammad Hajizeinali, Hamidreza Poorhosseini, Mojtaba Salarifar, Younes Nozari, Elham Hakki Kazazi
Background: The biolimus-eluting stent (BES), with a biodegradable polymer, has not been previously compared with the everolimus-eluting stent (EES), as a second-generation drug-eluting stent (DES).We sought to compare the 1-year outcome between the PROMUS(™) stent (EES type) and the BioMatrix(™) stent (BES type). Methods: From March 2008 to September 2011, all patients treated with the PROMUS™ stent or the BioMatrix™ stent for coronary artery stenosis at Tehran Heart Center were enrolled. The primary end points were 1-year adverse events, comprising death, myocardial infarction, target vessel revascularization, and target lesion revascularization...
April 13, 2016: Journal of Tehran Heart Center
https://www.readbyqxmd.com/read/27928224/clinical-outcomes-of-elderly-south-east-asian-patients-in-primary-percutaneous-coronary-intervention-for-st-elevation-myocardial-infarction
#4
Jieli Tong, Wen Wei Xiang, An Shing Ang, Wen Jun Sim, Kien Hong Quah, David Foo, Paul Jau Lueng Ong, Hee Hwa Ho
OBJECTIVE: To evaluate the clinical characteristics and in-hospital outcomes of elderly South-East Asian patients undergoing primary percutaneous coronary intervention (PPCI). METHODS: From January 2009 to December 2012, 1268 patients (86.4% male, mean age of 58.4 ± 12.2 years) presented to our hospital for ST-elevation myocardial infarction (STEMI) and underwent PPCI. They were divided into two groups: elderly group defined as age ≥ 70 years and non-elderly group defined as age < 70 years...
October 2016: Journal of Geriatric Cardiology: JGC
https://www.readbyqxmd.com/read/27924213/drug-eluting-stents-appear-superior-to-bare-metal-stents-for-vein-graft-pci-in-vessels-up-to-a-stent-diameter-of-4-mm
#5
Oliver P Guttmann, Daniel A Jones, Kassem A Safwan, Sean Gallagher, Krishnaraj S Rathod, Steve Hamshere, Elliot J Smith, Ajay K Jain, Anthony Mathur, Andrew Wragg, Charles J Knight, Roshan Weerackody
BACKGROUND: Research trials have shown improved short-term outcome with drug-eluting stents (DES) over bare metal stents (BMS) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI), primarily by reducing target vessel revascularization (TVR) for in-stent restenosis. We compared the outcomes in patients undergoing SVG stent implantation treated with DES or BMS. In exploratory analyses we investigated the influence of stent generation and diameter. METHODS: Data were obtained from a prospective database of 657 patients who underwent PCI for SVG lesions between 2003 and 2011...
January 2016: Heart International
https://www.readbyqxmd.com/read/27923461/impact-of-patient-and-lesion-complexity-on-long-term-outcomes-following-coronary-revascularization-with-new-generation-drug-eluting-stents
#6
Konstantinos C Koskinas, Masanori Taniwaki, Fabio Rigamonti, Dik Heg, Marco Roffi, David Tüller, Olivier Muller, Andre Vuillomenet, Stephane Cook, Daniel Weilenmann, Christopher Kaiser, Peiman Jamshidi, Peter Jüni, Stephan Windecker, Thomas Pilgrim
Long-term clinical outcomes of new-generation drug-eluting stents in complex anatomic and clinical settings are not well defined. This study assessed the impact of patient and lesion complexity on 2-year outcomes after coronary revascularization with ultrathin strut biodegradable-polymer (BP) sirolimus-eluting stents (SES) versus durable-polymer (DP) everolimus-eluting stents (EES). In a prespecified analysis of the BIOSCIENCE randomized trial (NCT01443104), complex patients (911 of 2,119; 43%) were defined by the presence of acute ST-elevation myocardial infarction (MI); left ventricular ejection fraction ≤30%; renal dysfunction; insulin-treated diabetes; treatment of ostial lesion, bypass graft, unprotected left main lesion; or 3-vessel intervention...
November 16, 2016: American Journal of Cardiology
https://www.readbyqxmd.com/read/27922807/comparing-drug-eluting-stents-to-bare-metal-stents-for-saphenous-vein-graft-lesion-pci
#7
EDITORIAL
Subhash Banerjee, Emmanouil S Brilakis
No abstract text is available yet for this article.
December 2016: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/27922693/a-novel-pdgf-receptor-inhibitor-eluting-stent-attenuates-in-stent-neointima-formation-in-a-rabbit-carotid-model
#8
Chen Huang, Haijun Mei, Min Zhou, Xiaobing Zheng
A novel drug-eluting stent (DES) is required to target vascular smooth muscle cells (SMCs) without harming endothelial cells (ECs). Platelet-derived growth factor (PDGF) is critical for the proliferation and migration of SMCs. Sunitinib [a PDGF receptor (PDGFR) tyrosine kinase inhibitor]‑eluting stents may therefore inhibit neointimal formation. The aim of the present study was to examine the stent‑based delivery of sunitinib in a rabbit carotid model; in addition, the effects of sunitinib were evaluated in vitro...
December 5, 2016: Molecular Medicine Reports
https://www.readbyqxmd.com/read/27920235/successful-reversal-of-bradycardia-and-dyspnea-with-aminophylline-after-ticagrelor-load
#9
Sarah A Minner, Pamela Simone, Benjamin B Chung, Atman P Shah
A 69-year-old male underwent elective percutaneous coronary intervention requiring placement of a drug-eluting stent to the first obtuse marginal artery. Four hours following the administration of a ticagrelor loading dose, he developed dyspnea and sinus pauses. Aminophylline was administered and resulted in immediate and sustained symptom resolution. Ticagrelor has been associated with dyspnea and bradyarrhythmias, both attributed to increased adenosine exposure. Ticagrelor inhibits reuptake of intracellular adenosine...
December 5, 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/27916744/does-acute-coronary-syndrome-impact-on-the-incidence-of-thrombosis-after-the-implantation-of-absorb-bioresorbable-vascular-scaffold
#10
Yohei Sotomi, Yosuke Miyazaki, Carlos Colet, Taku Asano, Pannipa Suwannasom, Jan Tijssen, Robbert J de Winter, Ron Waksman, Michael J Lipinski, Yoshinobu Onuma, Patrick W Serruys
AIMS: In the drug eluting stent (DES) era, patients with acute coronary syndrome (ACS) had a higher risk of early stent thrombosis compared with stable patients. The present study evaluated whether the same is true for the bioresorbable vascular scaffold (BVS: Abbott Vascular, Santa Clara CA). METHODS AND RESULTS: We assessed the relationship between the incidence of definite/probable scaffold thrombosis (ScT) (overall ScT and early ScT) and ACS percentage with the latest publications including the most recent large randomized controlled trials...
December 6, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27916002/long-term-effect-of-stents-eluting-6-mercaptopurine-in-porcine-coronary-arteries
#11
Matthijs S Ruiter, Albert Doornbos, Vivian de Waard, Robbert J de Winter, Nico J M Attevelt, Rob Steendam, Carlie J M de Vries
BACKGROUND: Drug-eluting stents (DES) have dramatically reduced restenosis rates compared to bare metal stents and are widely used in coronary artery angioplasty. The anti-proliferative nature of the drugs reduces smooth muscle cell (SMC) proliferation effectively, but unfortunately also negatively affects endothelialization of stent struts, necessitating prolonged dual anti-platelet therapy. Cell-type specific therapy may prevent this complication, giving rise to safer stents that do not require additional medication...
December 5, 2016: Journal of Negative Results in Biomedicine
https://www.readbyqxmd.com/read/27914991/antiplatelet-therapy-in-patients-with-glucose-6-phosphate-dehydrogenases-deficiency-after-percutaneous-coronary-intervention-a-reappraisal-for-clinical-and-interventional-cardiologists
#12
REVIEW
Marco Zuin, Gianluca Rigatelli, Mauro Carraro, Maria Paola Galasso, Fabio Dell'Avvocata, Rossella Paolini, Giovanni Zuliani, Loris Roncon
Glucose-6-phosphate dehydrogenase (G6PD) deficiency represents one of the most common erythrocyte enzymopathy. In the era of drug-eluting stents (DESs), the use of prolonged dual antiplatelet therapy (DAPT) with aspirin (ASA) and thienopyridine (clopidogrel or ticlopidine) has become mandatory in the treatment of patients with acute coronary syndromes (ACS) and/or after percutaneous coronary intervention (PCI). However, the use of ASA, and more in general of antiplatelet drugs in patients with G6PD deficiency remains controversial, also for the absence of specific guidelines and scientific evidences...
November 28, 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/27914492/ticagrelor-with-aspirin-or-alone-in-high-risk-patients-after-coronary-intervention-rationale-and-design-of-the-twilight-study
#13
Usman Baber, George Dangas, David J Cohen, C Michael Gibson, Shamir R Mehta, Dominick J Angiolillo, Stuart J Pocock, Mitchell W Krucoff, Adnan Kastrati, E Magnus Ohman, Philippe Gabriel Steg, Juan Badimon, M Urooj Zafar, Jaya Chandrasekhar, Samantha Sartori, Melissa Aquino, Roxana Mehran
BACKGROUND: Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Antiplatelet monotherapy with a potent P2Y12 receptor antagonist may reduce bleeding while maintaining anti thrombotic efficacy compared with conventional DAPT. METHODS: TWILIGHT is a randomized, double-blind placebo-controlled trial evaluating the comparative efficacy and safety of antiplatelet monotherapy versus DAPT in up to 9000 high-risk patients undergoing PCI with DES...
December 2016: American Heart Journal
https://www.readbyqxmd.com/read/27914490/bleeding-risk-following-percutaneous-coronary-intervention-in-patients-with-diabetes-prescribed-dual-anti-platelet-therapy
#14
Anna Grodzinsky, Suzanne V Arnold, Tracy Y Wang, Praneet Sharma, Kensey Gosch, Philip G Jones, Deepak L Bhatt, Philippe Gabriel Steg, Darren K McGuire, David J Cohen, John A Spertus, Adnan K Chhatriwalla, Marcus Lind, Garth Graham, Mikhail Kosiborod
BACKGROUND: Patients with diabetes mellitus (DM) experience higher rates of in-stent restenosis and greater benefit from drug-eluting stents implant at the time of percutaneous coronary intervention (PCI), necessitating prolonged dual anti-platelet therapy (DAPT). While DAPT reduces risk of ischemic events post-PCI, it also increases risk of bleeding. Whether bleeding rates differ among patients with and without DM, receiving long-term DAPT is unknown. METHODS: Among patients who underwent PCI and were maintained on DAPT for 1 year in a multicenter US registry, we assessed patient-reported bleeding over one year following PCI in patients with and without DM...
December 2016: American Heart Journal
https://www.readbyqxmd.com/read/27914489/rationale-and-design-of-the-east-west-late-lumen-loss-study-comparison-of-late-lumen-loss-between-eastern-and-western-drug-eluting-stent-study-cohorts
#15
Robert W Harrison, Vaishnavi Radhakrishnan, Peter S Lam, Dominic J Allocco, Sandeep Brar, Martin Fahy, Rebecca Fisher, Fumiaki Ikeno, Philippe Généreux, Takeshi Kimura, Minglei Liu, Weng Kit Lye, Gary S Mintz, Hirofumi Nagai, Yuka Suzuki, Roseann White, John C Allen, Mitchell W Krucoff
BACKGROUND: The contemporary evaluation of novel drug-eluting stents (DES) includes mechanistic observations that characterize postdeployment stent behavior. Quantification of late lumen loss due to neointimal hyperplasia 8-13 months after stent implantation, via quantitative coronary angiography (QCA), constitutes such an observation and is required by most regulatory authorities. Late lumen loss, as determined by QCA, has been validated as a surrogate for clinical endpoints such as target vessel revascularization...
December 2016: American Heart Journal
https://www.readbyqxmd.com/read/27914488/safety-of-6-month-duration-of-dual-antiplatelet-therapy-after-percutaneous-coronary-intervention-in-patients-with-acute-coronary-syndromes-rationale-and-design-of-the-smart-angioplasty-research-team-safety-of-6-month-duration-of-dual-antiplatelet-therapy-after
#16
Joo Myung Lee, Deok-Kyu Cho, Joo-Yong Hahn, Young Bin Song, Taek Kyu Park, Ju-Hyeon Oh, Jin Bae Lee, Joon-Hyung Doh, Sang-Hyun Kim, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuck Choi, Sang Hoon Lee, Hyeon-Cheol Gwon
BACKGROUND AND RATIONALE: Dual antiplatelet therapy (DAPT) is a fundamental treatment that optimizes clinical outcomes after percutaneous coronary intervention, especially in patients with acute coronary syndrome (ACS). Although current international guidelines recommend DAPT for at least 12 months after implantation of a drug-eluting stent in patients with ACS, these recommendations are not based on randomized controlled trials dedicated to ACS population. STUDY DESIGN: The SMART-DATE trial is a prospective, multicenter, randomized, and open-label study to demonstrate the noninferiority of 6-month DAPT compared with 12 months or longer DAPT in patients with ACS undergoing percutaneous coronary intervention...
December 2016: American Heart Journal
https://www.readbyqxmd.com/read/27914270/surface-mediated-transfection-of-a-pdna-vector-encoding-short-hairpin-rna-to-downregulate-tgf-%C3%AE-1-expression-for-the-prevention-of-in-stent-restenosis
#17
He Zhang, Ke-Feng Ren, Hao Chang, Jin-Lei Wang, Jian Ji
In-stent restenosis is one of the most serious modes of failure of cardiovascular stent implant. Although drug-eluting stents have been proven to reduce in-stent restenosis, the nonspecific inhibitory effects of anti-proliferative drugs, such as rapamycin, result in delayed re-endothelialization and fatal late stent thrombosis. Although many studies have focused on promoting rapid re-endothelialization, a feasible method of reducing excessive extracellular matrix (ECM) production and cell proliferation might provide a promising way to efficiently inhibit the restenosis in vivo...
November 24, 2016: Biomaterials
https://www.readbyqxmd.com/read/27912202/bioresorbable-stents-current-and-upcoming-bioresorbable-technologies
#18
REVIEW
Hui Ying Ang, Heerajnarain Bulluck, Philip Wong, Subbu S Venkatraman, Yingying Huang, Nicolas Foin
Bioresorbable scaffolds (BRS) represent a novel horizon in interventional cardiology for the treatment of coronary artery disease. The technology was introduced to overcome limitations of current metallic drug-eluting stents such as late in-stent restenosis and permanently caging the vessel. The concept of the BRS is to provide temporal support to the vessel during healing before being degraded and resorbed by the body, promoting restoration of the vessel vasomotion. Currently, there are several BRS that are under development or already commercially available...
November 12, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27905013/impact-of-stent-type-and-prolonged-dual-antiplatelet-therapy-on-long-term-clinical-outcomes-in-hemodialysis-patients-with-coronary-artery-disease
#19
Masahiko Asami, Jiro Aoki, Tatsuyuki Sato, Shuzou Tanimoto, Mika Watanabe, Yu Horiuchi, Koichi Furui, Kentaro Yasuhara, Yu Sato, Takuya Hashimoto, Sen Yachi, Kazuhiro Hara, Kengo Tanabe
The aim of this study was to address 7-year clinical outcomes and impact of prolonged dual antiplatelet therapy (DAPT) after coronary stenting in hemodialysis patients. Our study included 123 consecutive hemodialysis patients who had undergone percutaneous coronary intervention with a drug-eluting stent (DES) or bare-metal stent (BMS) (DES: 64, BMS: 59) in our institution. We compared long-term clinical outcomes following DES with BMS implantation as well as clinical outcomes in patients on DAPT for ≥1 year (DAPT on group, 89) with those on DAPT for <1 year (DAPT off group, 34)...
November 30, 2016: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/27903028/-cardiovascular-morbidity-and-mortality-in-patients-with-kidney-disease
#20
Ivo Quack, Ralf Westenfeld
Patients with kidney disease have a significantly increased cardiovascular morbidity and mortality. Especially diabetics have an increased risk to develop renal insufficiency and cardiovascular events. Two recent studies show that the SGLT2 inhibitor Empagliflozin and the GLP1 agonist Liraglutid are able to lower the cardiovascular risk of type2 diabetics with renal insufficiency. Recent observations suggest that bradycardia and asystole are main triggers for sudden cardiac death in patients with chronic kidney disease...
November 2016: Deutsche Medizinische Wochenschrift
keyword
keyword
1063
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"